-

10:43:47 PM

EW Stock News

EW - Edwards Lifesciences Corp

11/27/22 10:25 AM

NYSE : EW

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable

RHEA-AI

positive

11/01/22 9:00 AM

NYSE : EW

buyback

EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE

Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $750 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $1.7 billion of shares

RHEA-AI

neutral

10/27/22 4:15 PM

NYSE : EW

earnings

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022.Third Quarter Highlights and OutlookQ3 sales of $1.32 billion grew 1 percent; constant currency 1 sales grew 7 percent Q3 TAVR sales grew 1

RHEA-AI

positive

10/20/22 7:05 AM

NYSE : EW

conferencesearnings

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 after the market closes on Thursday, October 27, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those

RHEA-AI

neutral

09/17/22 11:30 AM

NYSE : EW

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective

RHEA-AI

neutral

09/15/22 9:00 AM

NYSE : EW

fda approval

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral

RHEA-AI

very positive

09/12/22 9:05 AM

NYSE : EW

fda approval

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. The launch

RHEA-AI

very positive

08/17/22 8:30 AM

NYSE : EW

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR)."Delivering the PASCAL Precision system

RHEA-AI

very positive

07/28/22 4:15 PM

NYSE : EW

earnings

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022.Second Quarter Highlights and OutlookQ2 sales of $1.37 billion were flat versus an elevated prior year; underlying 1 sales grew 5 percent Q2 TAVR

RHEA-AI

positive

07/21/22 7:05 AM

NYSE : EW

conferencesearnings

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those results.To

RHEA-AI

neutral